About Atilus Pharma Private Limited
Data last updated:
Atilus Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 August 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24110MH2020PTC344095. Its GSTIN is 27AATCA8813D1ZG (Maharashtra). The company holds 3 GST registrations, all of them active.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Lomesh Vinod Shah and Niraj Vinod Shah.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Gala No.C – 168 1st Floor Akurli Industrial Estate Akurli Road Kandivali (East), Mumbai, Maharashtra, India – 400101.
As per the financials filed for FY 2025, the company reported a revenue of ₹8.68 Cr, a decline of 20% compared to the previous year. For the same year it recorded a net profit of ₹72.35 Lakh (net margin 8.3%) and EBITDA of ₹1.07 Cr (EBITDA margin 12.3%). Revenue has declined at a compounded annual rate (CAGR) of 1% over three years.
The company is associated with 1 brand: Atilus Pharma. As per MCA filings, the company has open charges of ₹20 Lakh on record. Court records list 8 cases involving the company, including 8 filed against it; 2 cases are pending.
For more details, the company can be reached via its website atiluspharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressGala No.C – 168 1st Floor Akurli Industrial Estate Akurli Road Kandivali (East), Mumbai, Maharashtra, India – 400101
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Atilus Pharma Private Limited
The main business activities of Atilus Pharma are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Atilus Pharma Private Limited FY 2025 filings available
Atilus Pharma Private Limited reported revenue of ₹8.68 Cr (down 20% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Atilus Pharma Private Limited
Revenue has declined at a compounded annual rate (CAGR) of 1% over three years, including a 20% fall in the latest year. EBITDA fell 19% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Atilus Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹1.07 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹72.35 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Atilus Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 12.3% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 8.3% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Atilus Pharma are in the company report.
Financial statements from FY 2021
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Atilus Pharma Private Limited
Atilus Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Aps Biotech Private Limited | ₹8.72 Cr (FY 2024) | •••• | •••• | 0.0% | •••• | Roorkee, Uttarakhand, India |
| Integra Life Sciences Private Limited | ₹8.72 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | New Delhi, Delhi, India |
| Priyadarshini Microtech Private Limited | ₹8.71 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Navi Mumbai, Maharashtra, India |
| Walter Healthcare Private Limited | ₹8.69 Cr (FY 2025) | •••• | •••• | 56.0% | •••• | Mohali, Punjab, India |
| Associated Formulations Private Limited | ₹8.68 Cr (FY 2025) | •••• | •••• | 33.0% | •••• | New Delhi, Delhi, India |
| Atilus Pharma Private Limited this company | ₹8.68 Cr (FY 2025) | •••• | •••• | -20.0% | •••• | Mumbai, Maharashtra, India |
| Runicha Healthcare Private Limited | ₹8.66 Cr (FY 2025) | •••• | •••• | 6057.0% | •••• | Dhule, Maharashtra, India |
| Pehal Life Sciences Private Limited | ₹8.66 Cr (FY 2024) | •••• | •••• | -33.0% | •••• | Mumbai, Maharashtra, India |
| Waxsen Lifescience Private Limited | ₹8.64 Cr (FY 2019) | •••• | •••• | -50.0% | •••• | Mumbai, Maharashtra, India |
| Apogen Remedies Private Limited | ₹8.63 Cr (FY 2025) | •••• | •••• | -35.0% | •••• | Siddipet, Telangana, India |
| Kanad Labs Private Limited | ₹8.63 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Nagpur, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Atilus Pharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Atilus Pharma Private Limited
Atilus Pharma Private Limited is audited by NIRAJ SANGHAVI & ASSOCIATES for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| NIRAJ SANGHAVI & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Atilus Pharma Private Limited
Atilus Pharma has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Lomesh Vinod Shah | Director | 19 Aug 2020 | 6 Years 1 Months | Current |
| Niraj Vinod Shah | Director | 19 Aug 2020 | 6 Years 1 Months | Current |
Ownership and Shareholding of Atilus Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Atilus Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jun 2022 | Hdfc Bank Limited | ₹20 Lakh | Open |
Total charge records: 1 View all charges
Legal Cases of Atilus Pharma Private Limited
Atilus Pharma Private Limited has 8 court cases on record: 8 filed against it. 2 cases are pending and 6 are disposed. Status as checked between 21 Sep 2026 and 03 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 8 | 8 | 2 |
Cases on record (5 of 8)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Pune, Maharashtra | Civil suit | Filed against the company by Medlius Pharma Private Limited | Pending |
| District court, South, Delhi | Cheque dishonour complaint | Filed against the company by Godrej Finance Limited | Pending |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by Tata Capital Financial Services Limited | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by Tata Capital Financial Services Limited | Disposed |
| District court, Pune, Maharashtra | Civil suit | Filed against the company by DCB Bank Limited | Disposed |
Full case history
All 8 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Atilus Pharma Private Limited
Atilus Pharma Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 12 overdue payments to 8 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 8)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Aariva Pharma Private Limited | •••• | •••• | •••• |
| Om Containers Pvt.Ltd. | •••• | •••• | •••• |
| Ovoid Pharmachem Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Perkin Laboratories | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 1 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Atilus Pharma Private Limited
Atilus Pharma operates one associated brand: Atilus Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| API manufacturing and supply in the healthcare sector from Mumbai, India. | atiluspharma.com |
Employees and EPFO Compliance at Atilus Pharma Private Limited
Atilus Pharma Private Limited has a workforce of 0 employees as of Sep 24, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Atilus Pharma Private Limited
Atilus Pharma Private Limited has 2 board changes on record since 2020: 2 appointments. The latest: Lomesh Vinod Shah was appointed as Director on 19 Aug 2020.
Credit Ratings, Litigation & Regulatory Alerts for Atilus Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Atilus Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Atilus Pharma Private Limited
Atilus Pharma has 3 GST registrations: 3 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AATCA8813D1ZG | Maharashtra | Active | 31 Aug 2020 |
| 27AATCA8813D2ZF | Maharashtra | Active | 24 Apr 2025 |
| 24AATCA8813D1ZM | Gujarat | Active | 11 Nov 2020 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Atilus Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atilus Pharma Private Limited
Atilus Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 August 2020 (6+ years old) and is registered under CIN U24110MH2020PTC344095.
Atilus Pharma reported revenue of ₹8.68 Cr for FY 2025 (down 20% YoY).
Atilus Pharma has 2 current directors:
- Lomesh Vinod Shah - Director
- Niraj Vinod Shah - Director
Atilus Pharma reported a net profit of ₹72.35 Lakh (net margin 8.3%) and EBITDA of ₹1.07 Cr (EBITDA margin 12.3%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Atilus Pharma is -1% over three years. In the latest year (FY 2025) revenue fell 20%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Atilus Pharma is 27AATCA8813D1ZG, registered in Maharashtra. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 27AATCA8813D2ZF (Maharashtra), 24AATCA8813D1ZM (Gujarat).
The CIN (Corporate Identification Number) of Atilus Pharma is U24110MH2020PTC344095. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Atilus Pharma has 8 court cases on record: 8 filed against it. 2 are pending.
Atilus Pharma was incorporated on 19 August 2020, making it 6+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Atilus Pharma by revenue are Aps Biotech Private Limited, Integra Life Sciences Private Limited, Priyadarshini Microtech Private Limited, Walter Healthcare Private Limited, Associated Formulations Private Limited and 5 more, all in the Pharma industry (Formulations).
Lomesh Vinod Shah was appointed as Director on 19 Aug 2020. Niraj Vinod Shah was appointed as Director on 19 Aug 2020.
Atilus Pharma has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 12 overdue payments to 8 micro and small suppliers. The latest return was filed on 30 Apr 2024.